ArticleFrontiers in psychiatry2020
Can Kratom (
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.Human psychopharmacology · 2022Pooled it
- Serotonin release mediates analgesia via opioidergic system and withdrawal symptoms in chronic kratom extract-treated mice.BMC complementary medicine and therapies · 2025Article
- Clinical Implications of Kratom (Current addiction reports · 2023Review
- [Kratom - a short review for pain medicine].Schmerz (Berlin, Germany) · 2022Review
- Long COVID, a comprehensive systematic scoping review.Infection · 2021Article
- Kratom use for depression/anxiety self-management: challenges during the COVID-19 pandemic - A case report.Heliyon · 2021Article
- Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States.Frontiers in pharmacology · 2021Article
- Kratom (Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the symptoms of COVID-19 fever, general malaise, pain and aches, myalgia, fatigue, and headache can affect the quality of life of patients, even after the end of the acute phase of the infection and can be long lasting. The current treatment of these symptoms, also because COVID-19 patients have been asked not to use non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen are often unsatisfactory. Among the above mentioned symptoms malaise and fatigue seem the most difficult to treat. In this case report we describe the use of kratom (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.